Prasugrel Versus Ticagrelor
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Article, see p 1603
Head-to-head comparison of currently available therapies remains a significant challenge. As newer generation agents are developed, they are each compared against the prior standard of care to prove either superiority or noninferiority; however, they are rarely compared against each other. Cross-trial comparisons of efficacy and safety are fraught with hazard and should be interpreted with caution even when using the same control. Differences in trial design and conduct, management of control therapy, sample size and statistical power, and a host of other factors unrelated to the experimental therapy may influence each trial’s observed efficacy and safety. Although the availability of multiple therapeutic options for a given condition has advantages over a single agent, understanding whether 1 agent has superior efficacy and/or safety may be useful particularly when there are differences in cost, availability, or tolerability.
Within this context, the PRAGUE-18 trial (Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention) investigators should be congratulated for their effort to compare the efficacy of the 2 currently available potent P2Y12 antagonists that are favored for use in patients presenting with acute coronary syndromes.1 Both prasugrel and ticagrelor have been shown to be superior to clopidogrel in patients with acute coronary syndromes for reducing ischemic risk, but with increased bleeding, and have class I guideline recommendations in the United States and Europe.2,3 From the pivotal trials, including TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38) for prasugrel and PLATO (Study of Platelet Inhibition and Patient Outcomes) for ticagrelor, many have pointed to apparent differences in their observed efficacy and safety relative to clopidogrel, including the magnitude of efficacy, specific component end points reduced, safety, and tolerability. These …